 Galapagos NV NASDAQ: GLPG is chopping its pipeline to conserve cash while its business development team pursues a mission to find a transformative deal for the company. The company is ditching its Idiopathic pulmonary fibrosis IPF molecule 1205 while moving ahead with a Phase 2 IPF study for its chitinase inhibitor 4617. 